Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sexually active women, at risk for pregnancy and not planning to use condoms.~* Women in need for contraception and willing to use an oral contraceptive (OC) for 12 months (13 cycles).~* At least 18 but not older than 50 years of age at the time of screening.~* Body mass index (BMI) of \>/= 17 and \</= 35.~* Good physical and mental health.~* Willing to give informed consent in writing.~Exclusion Criteria:~* Contraindications for contraceptive steroids.~* In accordance with the Summary of Product Characteristics (SmPC)/Package Insert of DRSP-EE, additional~contraindications related to the antimineralocorticoid activity of drospirenone~(conditions that predispose to hyperkalemia):~* Renal insufficiency~* Hepatic dysfunction~* Adrenal insufficiency~* An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia \[CIN\],~Squamous Intraepithelial Lesion \[SIL\], carcinoma in situ, invasive carcinoma) at screening.~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.~* Use of an injectable hormonal method of contraception; within 6 months of an injection with a 3-month duration, within 4 months of an injection with a 2-month duration, within 2 months of an injection with a 1-month duration.~* Before spontaneous menstruation has occurred following a delivery or abortion.~* Breastfeeding or within 2 months after stopping breastfeeding prior to the start of trial medication.~* Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre- and posttreatment contraceptive method) and herbal remedies containing Hypericum perforatum (St John's Wort).~* Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- NOMAC-E2 (Type: EXPERIMENTAL): Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive
- DRSP-EE (Type: ACTIVE_COMPARATOR): Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive

Based on this trial design, predict the completion outcome and termination type (if applicable).